Click on image to view ad details and full-size version on AdPharm.

To see all of this brand’s ads on AdPharm, click here

Click on image to view ad details and full-size version on AdPharm

To see all of this brand’s ads on AdPharm, click here

Click on image to view ad details and full-size version on AdPharm

To see all of this brand’s ads on AdPharm, click here

PNH is destructive, progressive, and life threatening.
What will you do?

Soliris: The power to protect.
The first humanized monoclonal antibody (MAb) to reduce hemolysis and its harmful effects in all PNH patients.

Brand name: Soliris

Generic name/category: Eculizumab, Monoclonal antibodies, Immunosuppressants
Company: Alexion Pharmaceuticals
Country/Market: USA, North America
Indication(s)/use: Hemolysis reduction in Paroxysmal nocturnal haemoglobinuria (PNH)
Target: Healthcare Professionals (HCP)
Tagline: Soliris. The power to protect
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Blood – September 24, 2009

Click on thumbnail to view the full-size ad on AdPharm

Introducing Simponi.
The first monthly SC anti TNF a…

… all in one

-Proven efficacy in RA, As and PsA
-SmartJect autoinjector – designed to be patient-friendly
-Low injection volume (0.5 mL)
-Human lgG1k monoclonal antibody
-Patient support through the BioAdvantage Network

Monthly Simponi

The Simponi SmartJect autoinjector. Designed to be arthritis-patient-friendly.

Brand name: Simponi
Generic name/category: Golimumab, Monoclonal antibodies, TNF-alpha inhibitors
Company: Schering-Plough
Country/Market: Canada, North America
Indication(s)/use: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondilitis (AS)
Target: Healthcare Professionals (HCP)
Tagline: all in one
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: NEJM – September 24, 2009

To see all of this brand’s ads on AdPharm, click here

Click on thumbnail to view the full-size ad on AdPharm

When planning a treatment course for DLBCL
Take the essential path toward improved survival

Rituxan + CHOP is proven to prolong survival in DLBCL

Brand name: Rituxan
Generic name/category: Rituximab, Monoclonal antibodies, Orphan drugs, Antineoplastic drugs
Company: Genentech BioOncology and Biogen idec
Country/Market: USA, North America
Indication(s)/use: diffuse large B cell lymphoma (DLBCL)
Target: Healthcare Professionals (HCP)
Tagline: Take the essential path toward improved survival
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 6, 2009

To see all of this brand’s ads on AdPharm, click here